1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer,136, E359–E386.
2. Taslimi, Y., Zahedifard, F., Habibzadeh, S., Taheri, T., Abbaspour, H., Sadeghipour, A., et al. (2016). Antitumor effect of IP-10 by using two different approaches: Live delivery system and gene therapy. Journal of Breast Cancer,19, 34–44.
3. Alirezapour, B., Jalilian, A. R., Bolourinovin, F., & Moradkhani, S. (2013). Production and quality control of [67 Ga]-DOTA-trastuzumab for Radioimmunoscintigraphy. Iranian Journal of Pharmaceutical Research,12, 355–366.
4. Hajighasemlou, S., Alebouyeh, M., Rastegar, H., Manzari, M. T., Mirmoghtadaei, M., Moayedi, B., et al. (2015). Preparation of immunotoxin herceptin-botulinum and killing effects on two breast cancer cell lines. Asian Pacific Journal of Cancer Prevention,16, 5977–5981.
5. Moghimi, S. M., Rahbarizadeh, F., Ahmadvand, D., & Parhamifar, L. (2013). Heavy chain only antibodies: A new paradigm in personalized HER2+ breast cancer therapy. BioImpacts,3, 1–4.